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Abstract. Soft tissue sarcomas (STSs) are a heterogeneous 
group of mesenchymal tumors of >50 subtypes. However, 
STSs represent <1% of types of cancer. Despite this low 
frequency, the disease is aggressive and treatment, when 
possible, is based on traditional chemotherapies. A number of 
cases of resistance to adjuvant therapies have been reported. 
Metastases are commonly identified in STS patients during 
diagnosis and the development of effective clinical parameters 
is crucial for correct management of the disease. The use of 
biological markers in cancer is a useful tool to determine 
patient prognosis. Ki-67 is a protein marker for proliferation 
of somatic cells and is widely used in prognostic studies of 
various types of tumor, including STSs. Cluster of differentia-
tion 100 (CD100) is a member of the semaphorin family. The 
family was initially described as axon guidance molecules 
important for angiogenesis, organogenesis, apoptosis and 
neoplasia. CD100 was previously utilized as a prognostic 
factor in tumors and also in STSs. In the present study, protein 
expression of Ki-67 and CD100 was analyzed by immunohis-
tochemistry in samples of STS patients of the Barretos Cancer 
Hospital (Barretos, Brazil) to establish prognostic criteria of 
the disease. Results demonstrate a correlation between CD100 
expression and poor prognosis, consistent with a previous 
study. Moreover, the expression of Ki‑67 was identified to 
correlate with presence of local or locoregional recurrence. 
To the best of our knowledge, no large casuistic study has 
revealed this correlation between Ki-67 and local recurrence 
in STSs. The use of Ki-67 and CD100 as markers in clinical 
pathological analysis may be suitable as a prognostic criterion 
in disease progression.
Introduction
Soft tissue sarcomas (STSs) are a heterogeneous group of 
malignant neoplasias of >50 subtypes of mesenchymal origin. 
These tumors represent <1% of all types of cancer and their 
classification is based on histological morphology of the 
tumors (1). STS incidence is low, annually affecting ~200,000 
individuals worldwide. However, these neoplasias are aggres-
sive and the treatment, when possible, is based on traditional 
chemotherapies often associated with resistance. STS cells 
have been identified to originate from various cell lines, which 
explains, in part, the variety of phenotype characteristics 
observed in this tumor (1-3).
Metastases in STS patients are frequently identified at 
diagnosis and consequently, the correct utilization of trea-
ment parameters during disease managment is important (4). 
Histological grade, size, depth of tumor and status of surgical 
resection are currently used as prognostic factors for STS. 
Nevertheless, histological grade is currently the best criterion 
to determine tumor aggressiveness (2). At present, various 
molecules associated with the biological behavior of these 
tumors have been described for STSs and may improve clinical 
diagnosis (4).
Ki-67 is a well-known protein located in the nucleus and 
nucleolus of cells and is associated with proliferation of somatic 
cells. Ki-67 is absent in quiescent cells (5). For this reason, 
human Ki-67 protein is an efficient immunohistochemical 
marker for establishing levels of malignant cell proliferation 
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and is widely used in the diagnosis of several types of human 
tumor, including STSs (6). High expression of Ki-67 protein 
in STSs, is frequently associated with poor prognosis (7), 
including the occurrence of distant metastases (8).
Cluster of differentiation 100 (CD100) protein is an addi-
tional immunohistochemical marker of various types of tumor. 
CD100, also known as Semaphorin 4D (Sema4D), is a homodi-
meric glycoprotein markedly expressed in lymphoid tissue, 
skeletal muscle and at lower levels in the human brain (9). 
CD100 has been identified in two forms, membrane‑anchored 
and soluble. Membrane and soluble forms function as a 
receptor with high‑affinity to Plexin B1 or a ligand to the low 
affinity receptor, CD72, respectively (10,11). Semaphorins 
were primarily classified as axon guidance molecules (12‑14). 
However, this family is also involved in angiogenesis, 
organogenesis, apoptosis and neoplasia (15-18), as well as 
in human immune responses (19) where CD100 functions 
as a ligand or receptor to modulate the activities of B and T 
lymphocytes. In addition, CD100 interaction with Plexin B1 
induces migration and tubulogenesis of endothelial cells (20). 
CD100 is involved in a molecular pathway with Plexin B1 
and Met to promote invasive growth of malignant epithelial 
cells (21). Ch'ng et al (22) previously reported a correlation 
between CD100 and poor prognosis in STSs. Accordingly, 
CD100 is involved in various mechanisms of tumor progres-
sion, including angiogenesis, invasive growth and regulation of 
tumor-associated macrophages (23). 
The aim of the present study was to evaluate Ki-67 and 
CD100 expression in STS patient samples from Barretos 
Cancer Hospital (Barretos, Brazil) to determine whether, in 
the current population sample, reproducible results of the 
markers as effective prognostic factors in STSs are obtained. 
Results demonstrate that CD100 is an indicator of poor prog-
nosis in STSs, consistent with the results of Ch'ng et al (22). 
Furthermore, Ki‑67 expression in these tumors was identified 
as an effective prognostic tool capable of predicting local 
recurrence. To the best of our knowledge the current study is 
the first description of the use of Ki‑67 as an indicator of local 
recurrence in STSs.
Materials and methods
Patients. Sixty-five patients with STSs were treated at the 
Department of Orthopaedic Oncology of Barretos Cancer 
Hospital (Barretos, Brazil) between 2000 and 2009. Of these 
patients, 42 (64.6%) were male and 23 (35.4%) were female. 
Patients were predominantly Caucasian (43, 66.2%) and 38 
(58.5%) were from São Paulo. Among the patients, 36 cases 
(55.4%) came to the Hospital following previous treatment 
and 35 cases (53.8%) arrived with advanced disease (M1). 
Of the individuals who arrived with M1, the lung was the 
most frequent site of distant metastasis, representing 31 cases 
(88.6%). The average lag time was 15 months (SD=19.7). Only 
one tumor was classified as benign neoplasia. The tumors 
were located in the lower and upper limbs at a frequency of 44 
(67.7%) and 21 (32.3%) patients, respectively.
Tumors were classified as low grade, histological grades I 
and II (41.5%); and high grade, histological grade III (58.5%). 
Chemotherapy was performed in 32 patients (49.2%) and 
radiotherapy in 33 patients (50.8%). Resection was the most 
common surgery and was performed in 44 patients (68.8%), 
followed by amputation in 20 patients (31.3%). One patient 
did not undergo a surgical proceedure. During the follow-up, 
28 patients died (43.1%) and 32 relapsed (49.2%). Of all 
recurrences, 24 (75.0%) had local recurrence. Mean patients 
follow-up of was 45 months.
Histological samples. Paraffin blocks of tumor samples 
were obtained from 65 patients diagnosed with STS from 
the Department of Pathology and treated by Orthopaedic 
Oncology (Barretos Cancer Hospital). Areas free of tumor 
involvement were used as control samples. The confirmation 
Table I. Distribution of histological classification.
Histological classification n %
Pleomorphic sarcoma 14 21.54
Leiomyosarcoma 13 20.00
Myxoid liposarcoma 12 18.46
Myxofibrosarcoma 3 4.62
Sarcoma fibromyxoid 3 4.62
No specified origin sarcoma 3 4.62
Fibrosarcoma 2 3.08
Fibrosarcoma sclerosing 2 3.08
Synovial sarcoma 2 3.08
Synovial sarcoma monophasic 2 3.08
Fibromatosis 1 1.54
Hemangioperycitoma 1 1.54
Round cell liposarcoma 1 1.54
Dediferentiated liposarcoma  1 1.54
Pleomorphic liposarcoma  1 1.54
Pleomorphic rhabdomyosarcoma  1 1.54
Clear cell sarcoma 1 1.54
Biphasic synovial sarcoma  1 1.54
Metastatic synovial sarcoma 1 1.54
Table II. Distribuition of Ki-67 and CD100 expression.
Variable n %
Ki-67
  Negative 26 40.0
  + 18 27.7
  ++ 12 18.5
  +++ 9 13.8
CD100
  Negative 12 18.5
  + 16 24.6
  ++ 16 24.6
  +++ 21 32.3
CD100 + Ki-67
  Negative/+ 18 27.7
  ++/+++ 47 72.3
CD100, cluster of differentation 100.
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of the quality and the pathological diagnosis of all samples 
was performed by a pathologist. Following selection of cases, 
socio-demographic and clinical data were collected from 
patient medical records to characterize the samples. The 
distribution of the histological classification of tumors was 
performed according to the World Health Organization (1) and 
is depicted in Table I.
Immunohistochemistry. Following deparaffinization and 
rehydration of samples, antigen retrieval was performed 
using citrate buffer (10 mM, pH 6.0) for 30 min in a Pascal 
pressurized heating chamber (Dako, Carpinteria, CA, USA). 
Following cooling, the tissue samples were blocked in endog-
enous peroxidases (3% hydrogen peroxide in methanol). 
Subsequently, the material was incubated with normal horse 
serum or serum‑free protein (Dako) for 1 h to block non‑specific 
protein. Primary antibodies against the protein Ki-67 (Dako) 
and CD100 (Abcam, Cambridge, MA, USA) were applied to 
the samples according to the manufacturer's instructions, using 
the following dilutions: Ki-67 (1:100) and CD100 (1:100), with 
overnight incubation at 4˚C. Following this, peroxidase-conju-
gated secondary antibody (Abcam) or the amplifier polymer 
ADVANCE HRP detection system (Dako) were applied to the 
samples according to the manufacturer's instructions. Antibody 
binding was visualized using chromogen diaminobenzidine 
(Sigma-Aldrich, St. Louis, MO, USA) and counter-stained with 
hematoxylin. Positive controls for each primary antibody were 
used according to the manufacturer's instructions.
Evaluation of CD100 and Ki‑67. CD100 was evaluated on 
a scale from negative, +, ++, +++ and the stained surface 
area was calculated (stained surface area varied between 20 
and 100%). For Ki-67, only nuclear reaction was considered 
positive. Positive immunostaning was graded as follows: 
negative (0); faintly positive, between 1 and 10 (+); sporadic, 
>10 and 50 (++); and diffuse, >50 cells (+++) were positive. In 
statistical calculations, positive reactions of the markers were 
considered as positive or negative.
Table III. Estimation of global survival by Kaplan-Meier considering clinical variables/demographics.
   Survival probability (%)
   -------------------------------------------------------------------------- 
Variables Cases (n) Mortalities (n) 1 year 3 years 5 years P-value
Chemotherapy
  No 33 13 90.9 64.5 59.6 0.436
  Yes 32 15 84.4 49.2 49.2 
Radiotherapy
  No 32 13 84.4 54.7 54.7 0.861
  Yes 33 15 90.9 62.6 54.8 
Type of surgery
  Amputation 20   9 75.0 52.5 52.5 0.381
  Resection 44 19 93.2 62.6 56.7 
Histological grade
  I/II 27   7 100 84.1 74.2 0.001
  III 38 21 78.9 40.8 40.8 
Gender
  Female 23   8 91.3 67.3 67.3 0.223
  Male 42 20 85.7 54.9 46.5 
Ethnicity
  Caucasian 43 17 88.4 59.7 55.9 0.559
  Other 22 11 86.4 57.8 51.4 
Previous treatment
  No 29 15 86.2 48.9 44.0 0.177
  Yes 36 13 88.9 67.9 63.4 
Ki-67
  Negative 26   7 92.3 75.6 68.7 0.084
  + 18  9 77.8 54.5 48.5 
  ++/+++ 21 12 90.5 41.0 41.0 
CD100
  Negative 12   3 100 81.5 81.5 0.037
  + 16   4 100 68.9 68.9 
  ++/+++ 37 21 78.4 48.2 40.8 
CD100, cluster of differentiation 100.
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Images of histological sections were captured using the 
Eclipse 50i microscope coupled to a Sight DS-FI1 digital video 
camera (both from Nikon, Tokyo, Japan) and analyzed using 
the Image-Pro Express (v6.0; Media Cybernetics, Rockville, 
MD, USA).
Statistical analysis. Variables considered in this study for 
statistical analysis were: ethnicity, gender, histological grade, 
survival at 3 and 5 years and expression of CD100 and Ki-67. 
To characterize the study sample, data were summarized 
in terms of mean, standard deviation, median, minimum 
and maximum, when the variables were quantitative; and 
frequency and percentage for qualitative variables. Global, 
disease-free and local or locoregional disease-free survival 
were compared with the events, death from any cause, local 
recurrence and local and/or regional recurrence, respectively. 
Initially, the survival rates were estimated using a nonpara-
metric Kaplan-Meier estimator. The log-rank test was used 
to verify the difference between survival curves for various 
strata of the same variable. Following this, we used the Cox's 
multiple regression model to determine the effect of combi-
nations of variables. Data were correlated and analyzed with 
SPSS software (for Windows, v19.0). P<0.05 was considered to 
indicate a statistically significant difference.
Ethics. The present study was submitted to the Ethics 
Committee in Research (Barretos Cancer Hospital; 
no. 331/2010). Informed consent was not required as the study 
was a retrospective cohort. 
Results
Expression of Ki‑67 and CD100 markers in STS. Labeling of 
Ki-67 was negative in ~40% of tumor samples. Marker expres-
sion was considered low, moderate and severe in 27.7, 18.5 
and 13.8% of patient samples, respectively (Table II, Fig. 1). 
Patient samples (~18.5%) were negative for CD100, 24.6% had 
moderate and weak expression (each group) and 32.3% of the 
Table IV. Estimated local disease free survival by the Kaplan-Meier considering clinical variables/demographics.
   Survival probability (%) 
   -------------------------------------------------------------------------
Variables Cases (n) Recidives (n) 1 year 3 years 5 years P-value
Ethnicity 
  Caucasian 43 14 80.2 65.0 65.0 0.283
  Other 22 10 75.8 59.7 - 
Gender
  Female 23   8 82.2 70.9 57.3 0.474
  Male 42 16 76.6 58.3 58.2 
Histological grade
  I 27 10 85.2 70.0 65.3 0.298
  III 38 14 73.8 56.0 46.7 
Type of surgery
  Amputation 20   5 80.0 72.0 72.0 0.448
  Resection 44 19 78.3 59.9 52.9 
Previous treatment
  No 29 10 77.3 62.8 55.8 0.777
  Yes 36 14 79.8 63.4 58.1 
Chemotherapy
  No 33 11 87.2 67.1 56.3 0.363
  Yes 32 13 69.8 58.9 58.9 
Radiotherapy
  No 32   9 86.1 68.3 68.3 0.234
  Yes 33 15 72.0 58.3 48.6 
Ki-67
  Negative 26   8 88.5 75.5 69.2 0.016
  + 18   4 92.9 68.6 68.6 
  ++/+++ 21 12 55.1 50.1 - 
CD100
  Negative 12   4 100 91.7 62.9 0.298
  + 16   5 81.3 65.2 65.2 
  ++/+++ 37 15 69.8 51.3 51.3 
CD100, cluster of differentiation.
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samples were identified to exhibit marked expression of the 
molecule (Table II, Fig. 2).
Univariate and multivariate analysis for prognostic factors 
in STS. The histological grade of tumors was statistically 
significant (P=0.001) for the risk of death (global survival) 
in patients. Similarly, our results demonstrated a statisti-
cally significant correlation (P=0.037; Table III) between 
the increased expression of CD100 and decreased survival 
(Fig. 3). By contrast, the analysis of Ki-67 expression in tissues 
was not statistically significant when considering the overall 
disease-free survival. When evaluating additional variables, 
including chemotherapy, radiotherapy, surgery type, gender, 
ethnicity and previous treatment, any statistical significance 
was identified by an increase in overall survival.
In the assessment of local disease-free survival (Table IV) 
there was statistical significance for histological grade and 
expression of CD100. Again, the analysis of expression of 
Ki‑67, was unable to demonstrate the significance of local 
disease-free survival. In addition, other variables, including 
Figure 3. Kaplan-Meier estimate for global survival with respect to expres-
sion of CD100. CD100, cluster of differentiation.
Figure 4. Kaplan-Meier estimate for global survival with respect to expres-
sion of CD100. CD100, cluster of differentiation.
Figure 1. Immunohistochemistry for Ki-67. (A) High grade pleomorphic undifferentiated sarcoma, (B) high grade undifferentiated sarcoma (C) metastatic 
sinovial sarcoma.
Figure 2. Immunohistochemistry for CD100. (A) High grade indiferenciated pleomorphic sarcoma, (B) leiomyosarcoma grade III, (C) sclerosant epithelioid 
fibrosarcoma. CD100, cluster of differentiation.
  A
  C  B
  C  B
  A
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chemotherapy, radiotherapy, surgery type, gender, ethnicity 
and previous treatment do not show statistical significance.
Statistical analysis of local recurrence free survival (Table V) 
showed that the expression of Ki-67 in STS samples correlated 
significantly with the incidence of local recurrence in tumors. 
Fig. 4 presents the estimated nonparametric survival curve. 
Conversely, the evaluation of the expression of CD100 was not 
able to demonstrate significant for the event of local recurrence. 
Similarly, there was no significance to the event of local recur-
rence for the variables: chemotherapy, radiotherapy, surgery type, 
gender, ethnicity and pretreatment. In addition, the locoregional 
recurrence-free survival (Table V), the expression of Ki-67 
was again significant for the incidence of local recurrence and/
or regional STS and estimation of the survival curve is shown 
in Fig. 5. Similarly, the evaluation of the expression of CD100 
was not able to show significance for the event of recurrence. 
The other variables (chemotherapy, radiotherapy, surgery type, 
gender, ethnicity and previous treatment), were not able to predict 
the event of local recurrence and/or regional level in patients.
Figure 5. Kaplan-Meier estimate for locoregional recurrence free-survival 
with respect to expression of Ki-67.
Table V. Estimation of locoregional disease free survival by Kaplan-Meier considering clinical variables/demographics.
    Survival probability (%) 
   --------------------------------------------------------------------------- 
Variables Cases (n) Recidives (n) 1 year 3 years 5 years P-value
Chemotherapy
  No 33 16 77.3 52.6 33.1 0.661
  Yes 32 16 64.3 49.6 00.0 
Radiotherapy
  No 32 14 78.7 51.5 20.6 0.553
  Yes 33 18 63.6 49.5 40.5 
Type of surgery
  Amputation 20   7 74.7 56.9 56.9 0.541
  Resection 44 25 69.2 48.8 18.8 
Histological grade
  I/II 27 15 74.1 54.5 21.2 0.649
  III 38 17 68.9 48.3 40.3 
Gender
  Female 23 12 73.2 53.0 40.3 0.817
  Male 42 20 69.5 49.7 00.00 
Ethnicity
  Caucasian 43 21 73.1 49.3 28.8 0.769
  Other 22 11 66.0 54.2 - 
Previous treatment
  No 29 11 77.3 57.8 50.6 0.142
  Yes 36 21 65.7 46.0 0.00 
Ki-67
  Negative 26 10 84.4 66.2 0.00 0.006
  + 18   7 81.1 56.6 47.2 
  ++/+++ 21 15 50.3 25.9 12.9 
CD100
  Negative 12   5 91.7 81.5 0.00 0.101
  + 16   7 81.3 59.1 49.2 
  ++/+++ 37 20 55.3 35.8 35.8 
CD100, cluster of differentiation.
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In order to understand the behavior set of variables was 
used Cox's multiple regression model. In addition to the 
markers that were statistically significant considering the 
log-rank test were also adjusted variables: histological grade, 
chemotherapy, radiotherapy and pretreatment. The results 
of adjusting the Cox model are presented in Tables VI, VII 
and VIII for global survival, local disease-free survival and 
locoregional disease free survival, respectively. For global 
survival, only histological grade and CD100 were statistically 
significant (Table VI). Patients with histological grade I/II has 
0.16 risk of death as compared to patients with histological 
grade III, characterizing histological grades I/II as a protec-
tive factor. In evaluating the expression of CD100, patients 
with low expression (+), have 0.19 risk of death as compared 
to patients with higher expression (++/+++). Accordingly, low 
expression of CD100 (+), is a protective factor when compared 
Table VI. Estimate of relative risk by Cox multiple model for times of global survival.
    95% CI  
    ----------------------------------------  
Variables Cases (n) Mortalities (n) Relative risk Lower Upper P-value
Histological grade
  I/II 27 15 0.161 0.059 0.440 <0.001
  III 38 17 - - - -
Chemotherapy
  No 33 13 0.552 0.241 1.260 0.158
  Yes 32 15 - - - -
Radiotherapy
  No 32   9 1.132 0.513 2.500 0.759
  Yes 33 15 - - - -
Previous treatment
  No 29 15 2.476 2.476 1.096 5.593
  Yes 36 13 - - - -
CD100
  Negative 12   5 0.378 0.112 1.284 0.119
  + 16   7 0.192 0.063 0.586 0.004
  ++/+++ 37 20 - - - -
CD100, cluster of differentiation.
Table VII. Estimate of relative risk by Cox multiple model for times of local disease-free survival.
    95% CI   
    ----------------------------------------  
Variables Cases (n) Recidives (n) Relative risk Lower Upper P-value
Histological grade
  I/II 27 10 0.905 0.367 2.229 0.828
  III 38 14 - - - -
Chemotherapy
  No 33 11 0.780 0.328 1.857 0.575
  Yes 32 13 - - - -
Radiotherapy
  No 32   9 0.581 0.247 1.365 0.213
  Yes 33 15 - - - -
Previous treatment
  No 29 10 1.029 0.439 2.410 0.947
  Yes 36 14 - - - -
Ki-67
  Negative 26   8 0.338 0.127 0.903 0.030
  + 18   4 0.271 0.078 0.942 0.040
  ++/+++ 21 12 - -- - -
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with increased expression, represented here as patients with 
two or three crosses (++/+++). 
The negative expression for this marker was not significant 
at 0.05 and we hypothesize that this had occurred due to the 
low number of events associated with this result.
In the analysis of local disease-free survival and locore-
gional disease-free survival, only Ki-67 was a significant 
marker (Tables VII and VIII, respectively). In both cases, nega-
tive or low (+) Ki-67 expression is characterized as a protective 
factor compared with increased expression (++ or +++). For 
local disease-free survival, patients with negative Ki-67 expres-
sion have 0.28 times the chance of local recurrence, compared 
with higher expression of the molecule (++ or +++). Also, for 
the expression of low Ki-67 (+) the chance of local recurrence 
is 0.36. For locoregional disease-free survival, patients with 
negative Ki-67 expression have a 0.28 chance of local and/or 
regional recurrence as compared to those who present a higher 
expression of the marker (++ or +++). Low expression of the 
molecule (+) has a relative risk of 0.365 for locoregional recur-
rence.
Discussion
A number of previous studies have aimed to establish more 
effective prognostic criteria for STSs using parameters asso-
ciated with location and/or tumor size, histological grade or 
the expression of biomarkers in clinical samples (2,4). As a 
prognostic factor, histological grade is currently considered to 
be the most reliable marker for STSs (2). In the present study, 
histological grade showed a statistically significant (P=0.001) 
value for the risk of death (global disease-free survival) in 
patients. Histological grade is commonly analyzed to predict 
disease progression in STSs, was confirmed as a suitable 
marker for local and global survival analysis.
Previous studies have analyzed CD100 and Ki-67 levels in 
STSs. However, in the present study expression of CD100 and 
Ki-67 proteins in STSs was analyzed by immunohistochem-
istry in a patient population to establish their suitability as 
potential clinical prognostic markers. Expression of CD100 was 
identified to be significantly different in patients with high and 
decreased rates of survival (P=0.037). Ki-67 was not revealed 
to correlate with overall disease-free survival. This particular 
scenario was repeated when we evaluate the local disease-free 
survival that indicated significant value of histological grade 
and expression of CD100 for worse prognosis. Again, Ki-67 
expression was not associated with local disease-free survival. 
As discussed, CD100 is associated with a number of tumor-
igenic processes, including regulation of immune cells and 
angiogenesis (23). Recently, Kato et al (24) demonstrated that 
lymphocytes infiltrating pancreatic ductal adenocarcinoma 
overexpress Sema4D and its receptor Plexin B1. Levels of 
these molecules correlate with clinical factors, including poor 
prognosis and metastasis. In addition, Plexin B1 expression 
was identified to correlate with poor prognosis in ER-positive 
breast cancer (25). The potential of CD100 as a biomarker in 
STSs was confirmed in the current study (22). CD100 expres-
sion was identified to significantly correlate with global and 
local survival free of disease in patients, consistent with Ch'ng 
et al (22). Therefore, we conclude that CD100 expression levels 
are suitable for evaluation of tumors from STS patients to 
determine prognosis. 
CD100 expression levels were not identified to predict local 
relapse‑free survival in patients. Only Ki‑67 was identified as 
a biomarker for prediction of disease recurrence in patients, 
whereby local and locoregional recurrence-free survival was 
revealed to correlate with Ki-67 expression in tissues. Ki-67 
is expressed throughout the majority of the cell cycle and is 
considered to be an excellent marker of cell division (5,26). 
Table VIII. Estimate of relative risk by Cox multiple model for times of locoregional disease-free survival.
    95% CI  
    ---------------------------------------  
Variables Cases (n) Recidives (n) Relative risk Lower Upper P-value
Histological grade
  I/II 27 15 1.105 0.527 2.316 0.230
  III 38 17 - - - -
Chemotherapy
  No 33 16 0.814 0.383 1.731 0.593
  Yes 32 16 - - - -
Radiotherapy
  No 32 14 0.689 0.337 1.411 0.309
  Yes 33 18 - - - -
Previous treatment
  No 29 11 0.630 0.296 1.340 0.230
  Yes 36 21 - - - -
Ki-67
  Negative 26 10 0.279 0.115 0.679 0.005
  + 18 7 0.365 0.140 0.951 0.039
  ++/+++ 21 15 - - - -
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However, Ki-67 was not demonstrated to predict disease-free 
survival in global or local tumors. Several studies have reported 
Ki-67 as a prognostic factor in various tumor types (6). A 
number of previous studies have reported Ki-67 to be a poor 
prognostic factor (27,28). However, more recently the protein 
was identified as a marker of specific STS subtypes suitable 
for adjuvant therapy (29) as well as a predictive marker of 
distant tumor metastases (7,30). To date, a large casuistic study 
has not demonstrated the correlation of this cell proliferation 
marker with local recurrence in STSs. Only a single study with 
a limited number of cases of uterine sarcoma (gynecological 
sarcomas are not included in the current study), has identified a 
correlation between local recurrence and Ki-67 expression (31). 
The present study demonstrates that Ki-67 is a prognostic 
marker of local recurrence and/or locoregional relapse in STSs 
and may prove a suitable tool for the clinical management of 
disease progression. In addition, results demonstrate that CD100 
expression is an indicator of poor prognosis of STSs. The use of 
these markers in routine clinical pathology may be useful as an 
important prognostic criterion of disease progression.
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